Sino Biopharmaceutical Limited

SEHK:1177 Lagerbericht

Marktkapitalisierung: HK$64.4b

Sino Biopharmaceutical Management

Management Kriterienprüfungen 1/4

Sino Biopharmaceutical's CEO is Eric S. Y. Tse, appointed in Jul 2022, has a tenure of 2.33 years. total yearly compensation is CN¥49.69M, comprised of 45.4% salary and 54.6% bonuses, including company stock and options. directly owns 22.27% of the company’s shares, worth HK$14.35B. The average tenure of the management team and the board of directors is 1.8 years and 9.5 years respectively.

Wichtige Informationen

Eric S. Y. Tse

Geschäftsführender

CN¥49.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts45.4%
Amtszeit als Geschäftsführer2.3yrs
Eigentum des Geschäftsführers22.3%
Durchschnittliche Amtszeit des Managements1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder9.5yrs

Jüngste Management Updates

Recent updates

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Eric S. Y. Tse im Vergleich zu den Einnahmen von Sino Biopharmaceutical verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥50mCN¥23m

CN¥2b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022n/an/a

CN¥2b

Sep 30 2022n/an/a

CN¥5b

Jun 30 2022n/an/a

CN¥8b

Mar 31 2022n/an/a

CN¥14b

Dec 31 2021CN¥23mCN¥6m

CN¥15b

Sep 30 2021n/an/a

CN¥12b

Jun 30 2021n/an/a

CN¥10b

Mar 31 2021n/an/a

CN¥4b

Dec 31 2020CN¥25mCN¥7m

CN¥3b

Sep 30 2020n/an/a

CN¥2b

Jun 30 2020n/an/a

CN¥3b

Mar 31 2020n/an/a

CN¥3b

Dec 31 2019CN¥6mCN¥870k

CN¥3b

Vergütung im Vergleich zum Markt: Eric S. Y.'s total compensation ($USD7.01M) is above average for companies of similar size in the Hong Kong market ($USD640.18K).

Entschädigung vs. Einkommen: Eric S. Y.'s compensation has increased by more than 20% in the past year.

Geschäftsführer

Eric S. Y. Tse (28 yo)

2.3yrs

Amtszeit

CN¥49,691,000

Vergütung

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Y. Y. Tse
Executive Chairwoman of the Board9.4yrsCN¥49.69m0.033%
HK$ 21.2m
Eric S. Y. Tse
CEO & Executive Director2.3yrsCN¥49.69m22.27%
HK$ 14.4b
Ping Tse
Founder & Senior Executive Vice Chairman4.3yrsCN¥49.53m9.11%
HK$ 5.9b
Cheung Ling Cheng
Executive Vice Chairwoman of the Board7.6yrsCN¥43.13m16.31%
HK$ 10.5b
Zhoushan Tian
Executive Directorno dataCN¥1.91mkeine Daten
Hsin Tse
Senior VP & Executive Directorno dataCN¥6.41m1.96%
HK$ 1.3b
Chun Ling Li
Chief Financial Officer1.8yrskeine Datenkeine Daten
Song Jin
Vice President of Public Affairsno datakeine Datenkeine Daten
Sean Chen
Chief Strategy Officer1.8yrskeine Datenkeine Daten
Chau Ling Yu
Assistant VP & Financial Controllerno datakeine Datenkeine Daten
Oi Nin Chan
Company Secretary9.3yrskeine Datenkeine Daten
Toogood Ben
CEO of invoX & Head of Globalization1.8yrskeine Datenkeine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: 1177's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Y. Y. Tse
Executive Chairwoman of the Board9.4yrsCN¥49.69m0.033%
HK$ 21.2m
Eric S. Y. Tse
CEO & Executive Director5.1yrsCN¥49.69m22.27%
HK$ 14.4b
Ping Tse
Founder & Senior Executive Vice Chairman4.3yrsCN¥49.53m9.11%
HK$ 5.9b
Cheung Ling Cheng
Executive Vice Chairwoman of the Board7.6yrsCN¥43.13m16.31%
HK$ 10.5b
Zhoushan Tian
Executive Director9.6yrsCN¥1.91mkeine Daten
Hsin Tse
Senior VP & Executive Directorno dataCN¥6.41m1.96%
HK$ 1.3b
Zhengfei Lu
Independent Non-Executive Director19yrsCN¥376.00kkeine Daten
Dakui Li
Independent Non-Executive Director20.2yrsCN¥376.00kkeine Daten
Lu Fu Zhang
Independent Non-Executive Director9.6yrsCN¥376.00kkeine Daten
Hong Lu
Independent Non-Executive Director9.6yrsCN¥342.00kkeine Daten
Kwok Tung Li
Independent Non-Executive Director3.9yrsCN¥376.00k0.00039%
HK$ 251.3k

9.5yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: 1177's board of directors are considered experienced (9.5 years average tenure).